Home › All Companies › CADL › Annual Report

Candel Therapeutics, Inc. (CADL) — Annual Report

AI-Powered SEC Filing Analysis

← All CADL filings
Latest Annual Report Filed: 2026-03-12

Key Insights

  • Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company has licensed technology from Brigham and Women's Hospital and acquired assets from Peripagen Inc.
  • Candel has secured financing through a loan agreement with Trinity Capital Inc. and an at-the-market (ATM) offering. The company also has outstanding warrants that could provide additional funding if exercised.
  • Candel reported no revenue in 2024 and 2025, as it remains in the clinical development stage. The company's expenses are primarily related to R&D and general & administrative costs.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Candel Therapeutics, Inc.

Insider Trading Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.